Home

Download

Statistics

Landscape

Help

Contact

	Gene summary
	Datasets with differential expression of this gene
	Expression of this gene in the resistant group across all datasets and cell types
	Significant ligand-receptor pairs related to this gene (This gene does not contain this module)
	Known drug resistance mechanisms of this gene (This gene does not contain this module)
	MicroRNAs (miRNAs) regulating this gene
	Motifs and transcription factors (TFs) regulating this gene
	Acts as a transcription factor (This gene does not contain this module)
	Acts as a drug target< (This gene does not contain this module)

Gene: COTL1

Summary for COTL1

Gene information	Gene symbol	COTL1
	Ensembl ID	ENSG00000103187
	Entrez ID	23406
	Gene name	coactosin like F-actin binding protein 1
	Synonyms	CLP
	Gene type	protein_coding
	UniProtAcc	Q14019

Top

Dataset with differentially expressed gene: COTL1

Differentially expression genes between the resistant and sensitive groups. A positive avg_log2FC represents significantly high expression in the resistant group, while a negative avg_log2FC represents significantly low expression in the resistant group.

Dataset	Source	Tissue	Cancer type level1	Cancer type level2	Drug type	Regimen	Timepoint	Cell type	avg_log2FC	p_val_adj
GSE140440	DU145 and PC cell lines	Cell line	Prostate cancer	Prostate cancer	Chemotherapy	docetaxel	NA	Malignant cells	0.523294	1.61e-04
GSE186960	Panc1 cell line	Cell line	Pancreatic cancer	Pancreatic ductal adenocarcinoma (PDAC)	Chemotherapy	gemcitabine	NA	Malignant cells	0.301694	1.71e-20
GSE131984_Pac	SUM159 cell line	Cell line	Breast cancer	Triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	NA	Malignant cells	0.283141	3.27e-21
GSE163836	FCIBC02 cell line	Cell line	Breast cancer	Inflammatory breast cancer	Chemotherapy	paclitaxel	NA	Malignant cells	-0.513358	0.00e+00
GSE169246_PacBlood	patients	Peripheral blood mononuclear cells	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	post	cDCs	0.719683	1.89e-34
GSE169246_PacBlood	patients	Peripheral blood mononuclear cells	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	post	CD8+ T cells	0.450052	7.61e-16
GSE169246_PacBlood	patients	Peripheral blood mononuclear cells	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	pre	cDCs	0.29211	1.50e-07
GSE169246_PacBlood	patients	Peripheral blood mononuclear cells	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	pre	B cells	0.378909	0.00e+00
GSE169246_PacBlood	patients	Peripheral blood mononuclear cells	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	pre	Mono/Macro	-0.362115	0.00e+00
GSE169246_PacTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	post	NK cells	0.456817	1.55e-31
GSE169246_PacTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	post	B cells	0.50048	1.23e-15
GSE169246_PacTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	post	cDCs	0.430197	1.09e-06
GSE169246_PacTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	post	CD8+ T cells	0.494315	0.00e+00
GSE169246_PacTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	pre	CD8+ T cells	-0.322201	0.00e+00
GSE169246_PacAteBlood	patients	Peripheral blood mononuclear cells	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Immunotherapy	atezolizumab + paclitaxel	post	cDCs	-0.289832	1.60e-03
GSE169246_PacAteBlood	patients	Peripheral blood mononuclear cells	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Immunotherapy	atezolizumab + paclitaxel	post	Mono/Macro	-0.256669	4.25e-22
GSE169246_PacAteBlood	patients	Peripheral blood mononuclear cells	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Immunotherapy	atezolizumab + paclitaxel	post	CD8+ T cells	-0.322091	0.00e+00
GSE169246_PacAteBlood	patients	Peripheral blood mononuclear cells	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Immunotherapy	atezolizumab + paclitaxel	post	NK cells	-0.432813	0.00e+00
GSE169246_PacAteBlood	patients	Peripheral blood mononuclear cells	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Immunotherapy	atezolizumab + paclitaxel	pre	cDCs	0.428324	3.53e-12
GSE169246_PacAteTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Immunotherapy	atezolizumab + paclitaxel	pre	CD8+ T cells	-0.311829	0.00e+00
GSE197268_Axi-cel	patients	Peripheral blood mononuclear cells	Acute lymphoblastic leukemia	Large B-cell acute lymphoblastic leukemia (B-ALL)	Immunotherapy	axi-cel (CAR-T)	post	CD8+ T cells	0.596604	0.00e+00
GSE197268_Axi-cel	patients	Peripheral blood mononuclear cells	Acute lymphoblastic leukemia	Large B-cell acute lymphoblastic leukemia (B-ALL)	Immunotherapy	axi-cel (CAR-T)	post	CD4+ T cells	0.393197	1.04e-40
GSE197268_Axi-cel	patients	Peripheral blood mononuclear cells	Acute lymphoblastic leukemia	Large B-cell acute lymphoblastic leukemia (B-ALL)	Immunotherapy	axi-cel (CAR-T)	pre	CD4+ T cells	-0.35316	6.90e-17
GSE197268_Axi-cel	patients	Peripheral blood mononuclear cells	Acute lymphoblastic leukemia	Large B-cell acute lymphoblastic leukemia (B-ALL)	Immunotherapy	axi-cel (CAR-T)	pre	CD8+ T cells	-0.463979	0.00e+00
GSE197268_Axi-cel	patients	Peripheral blood mononuclear cells	Acute lymphoblastic leukemia	Large B-cell acute lymphoblastic leukemia (B-ALL)	Immunotherapy	axi-cel (CAR-T)	pre	NK cells	-0.29761	0.00e+00
GSE164551	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Immunotherapy	CAR-T	NA	CD4+ T cells	-0.606731	1.01e-12
GSE164551	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Immunotherapy	CAR-T	NA	CD8+ T cells	-0.524171	9.38e-04
PMID34715028	patients	Tumor tissue	Kidney cancer	Clear cell renal cell carcinoma (ccRCC)	Immunotherapy	nivolumab	post	CD8+ T cells	-0.461298	0.00e+00
PMID34715028	patients	Tumor tissue	Kidney cancer	Clear cell renal cell carcinoma (ccRCC)	Immunotherapy	nivolumab	post	CD4+ T cells	-0.386605	2.12e-34
GSE164237	patients	Peripheral blood mononuclear cells	Melanoma	Advanced stages of melanoma	Immunotherapy	pembrolizumab	pre	CD8+ T cells	-0.379647	0.00e+00
GSE207422_Sin	patients	Tumor tissue	Lung cancer	EGFR/ALK mutation negative non-small cell lung cancer (NSCLC)	Immunotherapy	sintilimab + carboplatin + (docetaxel or pemetrexed or emcitabine)	post	Mono/Macro	-0.323975	1.21e-02
GSE207422_Sin	patients	Tumor tissue	Lung cancer	EGFR/ALK mutation negative non-small cell lung cancer (NSCLC)	Immunotherapy	sintilimab + carboplatin + (docetaxel or pemetrexed or emcitabine)	post	pDCs	-1.26946	5.12e-04
GSE207422_Sin	patients	Tumor tissue	Lung cancer	EGFR/ALK mutation negative non-small cell lung cancer (NSCLC)	Immunotherapy	sintilimab + carboplatin + (docetaxel or pemetrexed or emcitabine)	post	Neutrophils	-0.451394	1.30e-21
GSE207422_Sin	patients	Tumor tissue	Lung cancer	EGFR/ALK mutation negative non-small cell lung cancer (NSCLC)	Immunotherapy	sintilimab + carboplatin + (docetaxel or pemetrexed or emcitabine)	post	CD8+ T cells	0.262629	4.89e-06
GSE197268_Tisa-cel	patients	Peripheral blood mononuclear cells	Acute lymphoblastic leukemia	Large B-cell acute lymphoblastic leukemia (B-ALL)	Immunotherapy	tisa-cel (CAR-T)	post	NK cells	0.330824	1.18e-14
GSE197268_Tisa-cel	patients	Peripheral blood mononuclear cells	Acute lymphoblastic leukemia	Large B-cell acute lymphoblastic leukemia (B-ALL)	Immunotherapy	tisa-cel (CAR-T)	pre	NK cells	-0.279345	0.00e+00
GSE207422_Tor	patients	Tumor tissue	Lung cancer	EGFR/ALK mutation negative non-small cell lung cancer (NSCLC)	Immunotherapy	toripalimab + carboplatin + (docetaxel or pemetrexed or emcitabine)	post	B cells	-0.63463	1.11e-03
GSE189460	patients	Bone marrow aspirate	Multiple myeloma	Multiple myeloma (MM)	Targeted therapy	bortezomib + melphalan + prednisolone	pre	B cells	0.366012	1.17e-03
GSE189460	patients	Bone marrow aspirate	Multiple myeloma	Multiple myeloma (MM)	Targeted therapy	bortezomib + melphalan + prednisolone	pre	Mono/Macro	0.261603	5.71e-32
GSE189460	patients	Bone marrow aspirate	Multiple myeloma	Multiple myeloma (MM)	Targeted therapy	bortezomib + melphalan + prednisolone	pre	CD8+ T cells	0.344343	5.35e-16
GSE161801_PI	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	carfilzomib + dexamethasone	post	B cells	-0.714769	1.66e-02
GSE161801_PI	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	carfilzomib + dexamethasone	post	Mono/Macro	-0.351928	1.29e-27
GSE161801_PI	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	carfilzomib + dexamethasone	post	NK cells	-0.396425	2.17e-24
GSE161801_PI	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	carfilzomib + dexamethasone	post	CD8+ T cells	-0.400011	0.00e+00
GSE139386	H3122 cell line	Cell line	Lung cancer	EML4-ALK fusion-positive non-small cell lung cancer (NSCLC)	Targeted therapy	ceritinib	NA	Malignant cells	-1.25262	0.00e+00
GSE162117	patients	Peripheral blood mononuclear cells	Acute myeloid leukemia	Tefractory acute myeloid leukemia (AML)	Targeted therapy	ficlatuzumab	post	Malignant cells	-0.477755	0.00e+00
GSE162117	patients	Peripheral blood mononuclear cells	Acute myeloid leukemia	Tefractory acute myeloid leukemia (AML)	Targeted therapy	ficlatuzumab	post	Erythrocytes	0.707973	6.72e-04
GSE199333	patients	Bone marrow aspirate	Acute myeloid leukemia	Primary FLT3-ITD-mutated acute myeloid leukemia (AML)	Targeted therapy	gilteritinib	post	B cells	1.54055	1.78e-05
GSE199333	patients	Bone marrow aspirate	Acute myeloid leukemia	Primary FLT3-ITD-mutated acute myeloid leukemia (AML)	Targeted therapy	gilteritinib	post	Malignant cells	-1.69593	0.00e+00
GSE199333	patients	Bone marrow aspirate	Acute myeloid leukemia	Primary FLT3-ITD-mutated acute myeloid leukemia (AML)	Targeted therapy	gilteritinib	post	CD4+ T cells	0.289115	5.24e-32
GSE199333	patients	Bone marrow aspirate	Acute myeloid leukemia	Primary FLT3-ITD-mutated acute myeloid leukemia (AML)	Targeted therapy	gilteritinib	pre	CD4+ T cells	-0.462631	3.13e-02
GSE199333	patients	Bone marrow aspirate	Acute myeloid leukemia	Primary FLT3-ITD-mutated acute myeloid leukemia (AML)	Targeted therapy	gilteritinib	pre	CD8+ T cells	-1.29324	1.11e-17
GSE199333	patients	Bone marrow aspirate	Acute myeloid leukemia	Primary FLT3-ITD-mutated acute myeloid leukemia (AML)	Targeted therapy	gilteritinib	pre	NK cells	-0.830434	1.99e-06
GSE199333	patients	Bone marrow aspirate	Acute myeloid leukemia	Primary FLT3-ITD-mutated acute myeloid leukemia (AML)	Targeted therapy	gilteritinib	pre	Malignant cells	-0.530098	0.00e+00
GSE111014	patients	Peripheral blood mononuclear cells	Chronic lymphocytic leukemia	Chronic lymphocytic leukemia (CLL)	Targeted therapy	ibrutinib	post	CD4+ T cells	-1.01622	2.71e-07
GSE111014	patients	Peripheral blood mononuclear cells	Chronic lymphocytic leukemia	Chronic lymphocytic leukemia (CLL)	Targeted therapy	ibrutinib	post	CD8+ T cells	-0.434497	1.08e-20
GSE111014	patients	Peripheral blood mononuclear cells	Chronic lymphocytic leukemia	Chronic lymphocytic leukemia (CLL)	Targeted therapy	ibrutinib	pre	CD4+ T cells	-0.713321	1.29e-04
GSE111014	patients	Peripheral blood mononuclear cells	Chronic lymphocytic leukemia	Chronic lymphocytic leukemia (CLL)	Targeted therapy	ibrutinib	pre	CD8+ T cells	-0.502451	1.18e-13
GSE131984_Pal	SUM159 cell line	Cell line	Breast cancer	Triple-negative breast cancer (TNBC)	Targeted therapy	palbociclib	NA	Malignant cells	-0.288941	7.77e-18
GSE161801_IMiD	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	pomalidomide + dexamethasone OR lenalidomide + dexamethasone	pre	Mono/Macro	-0.289757	6.61e-17
GSE161801_IMiD	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	pomalidomide + dexamethasone OR lenalidomide + dexamethasone	pre	cDCs	-0.367211	2.17e-03

Top

Expression of COTL1 in the resistant group across all datasets and cell types

Red dots represent significantly high expression in the resistant group, while blue dots represent significantly low expression in the resistant group. White dots represent that there is no significant difference in the expression of this gene between the resistant and sensitive groups. Blank represents that this cell type is not present in this dataset. (If the image exists, the user can click on it to enlarge it in a new window.)

Top

Significant ligand-receptor pairs related to COTL1

This table shows the significant ligand-receptor pairs related to this gene across all datasets, timepoints and conditions. (Complete files can be downloaded from the download section.)

Top

Known drug resistance mechanisms of this gene

This table shows the known drug resistance mechanisms of this gene. Clicking on this gene will link to another database that displays more drug resistance-related information.

Top

MicroRNAs (miRNA) regulating COTL1

This table shows the miRNAs with a score of more than 80 regulating this gene. (Complete files can be downloaded from the download section.)

Gene symbol	miRNA	Score	GeneBank accession
COTL1	hsa-miR-654-5p	91.6539	NM_021149
COTL1	hsa-miR-541-3p	91.6539	NM_021149
COTL1	hsa-miR-101-3p	89.5459	NM_021149
COTL1	hsa-miR-3686	87.2844	NM_021149
COTL1	hsa-miR-7111-5p	82.4342	NM_021149
COTL1	hsa-miR-6870-5p	82.4342	NM_021149
COTL1	hsa-miR-4723-5p	82.4342	NM_021149
COTL1	hsa-miR-5698	82.4342	NM_021149
COTL1	hsa-miR-6827-5p	82.3905	NM_021149
COTL1	hsa-miR-5006-5p	81.0693	NM_021149
COTL1	hsa-miR-4514	80.8726	NM_021149
COTL1	hsa-miR-4692	80.8726	NM_021149
COTL1	hsa-miR-548g-3p	80.1075	NM_021149

Page: 1

Top

Motifs and transcription factors (TFs) regulating COTL1

This table shows the Motifs and transcription factors (TFs) regulating this gene. (Complete files can be downloaded from the download section.)

Gene symbol	motif	TF_highConf
COTL1	jaspar__MA1708.1	ETV7 (directAnnotation).
COTL1	taipale_tf_pairs__ELK1_EOMES_RSCGGAANNAGGYGYNA_CAP_repr	ELK1; EOMES (directAnnotation).
COTL1	metacluster_22.18	BACH2 (inferredBy_Orthology).
COTL1	metacluster_145.10	ZNF24 (directAnnotation).
COTL1	kznf__ZNF182_Imbeault2017_OM_RCADE	ZNF182 (directAnnotation).
COTL1	hocomoco__BPTF_HUMAN.H11MO.0.D	BPTF (directAnnotation).
COTL1	transfac_pro__M05768	ZNF544 (directAnnotation).
COTL1	metacluster_174.6	NFYA; NFYB; NFYB; NFYC (directAnnotation).
COTL1	jaspar__MA0502.2	NFYB (directAnnotation).
COTL1	metacluster_144.8	ZNF30; ZNF30 (directAnnotation).
COTL1	metacluster_7.13	ZFX (directAnnotation).
COTL1	metacluster_144.3	ZNF704; ZNF704 (directAnnotation).
COTL1	transfac_pro__M01219	SP1 (directAnnotation). SP3 (inferredBy_Orthology).
COTL1	kznf__ZNF571_Imbeault2017_OM_RCADE	ZNF571 (directAnnotation).
COTL1	metacluster_191.1	ZNF528; ZNF528; ZNF528 (directAnnotation).
COTL1	transfac_pro__M05941	ZNF471 (directAnnotation).
COTL1	transfac_pro__M06568	ZNF501 (directAnnotation).
COTL1	jaspar__MA1945.1	FIGLA (directAnnotation).
COTL1	transfac_pro__M06493	ZNF668 (inferredBy_Orthology).
COTL1	transfac_pro__M06990	ZNF236 (directAnnotation).
COTL1	metacluster_52.6	ZSCAN29; ZSCAN29 (directAnnotation).
COTL1	jaspar__MA1941.1	FIGLA (directAnnotation).
COTL1	transfac_pro__M06607	ZNF560 (directAnnotation).
COTL1	transfac_pro__M06968	ZNF467 (inferredBy_Orthology).
COTL1	metacluster_10.31	MYC (directAnnotation).
COTL1	transfac_pro__M05933	ZNF552 (directAnnotation).
COTL1	taipale_tf_pairs__POU2F1_DLX2_TGMATATKCANNNNNTAATKR_CAP_repr	DLX2; POU2F1 (directAnnotation).
COTL1	taipale_tf_pairs__CLOCK_NHLH1_NRCAGCTGNNNNNCACGTGNN_CAP_repr	CLOCK; NHLH1 (directAnnotation).
COTL1	nitta__Ets98B_TTCCCC20NTA_KH_TKGCGGATGCN_m1_c3	SPDEF (inferredBy_Orthology).
COTL1	transfac_pro__M06045	ZNF729 (directAnnotation).
COTL1	jaspar__MA1633.2	BACH1 (directAnnotation).
COTL1	taipale_tf_pairs__TEAD4_HOXB13_NTCGTAAAATGC_CAP	HOXB13; TEAD4 (directAnnotation).
COTL1	taipale_tf_pairs__TEAD4_HES7_RCATTCCNNCRCGYGYN_CAP_repr	HES7; TEAD4 (directAnnotation).
COTL1	transfac_pro__M06741	ZNF70 (directAnnotation).
COTL1	jaspar__MA0033.2	FOXL1 (directAnnotation).
COTL1	metacluster_108.1	ZNF101; ZNF697 (directAnnotation).
COTL1	transfac_pro__M06075	ZNF197 (directAnnotation).
COTL1	tfdimers__MD00046	GATA1; GATA2; GATA3; GATA4; GATA5; GATA6; SMAD4 (directAnnotation).
COTL1	taipale_tf_pairs__ETV2_HES7_RSCGGAANNNNNNCACGTGNN_CAP_repr	ETV2; HES7 (directAnnotation).
COTL1	transfac_pro__M06231	ZNF273 (directAnnotation).
COTL1	transfac_pro__M06344	ZNF530 (directAnnotation).
COTL1	taipale_tf_pairs__GCM1_ELK3_ACCCGCANCCGGAAGN_CAP_repr	ELK3; GCM1 (directAnnotation).
COTL1	metacluster_134.4	AHDC1; ARID5B; FOXA1; FOXA1; FOXA2; FOXA2; FOXA3; FOXA3; FOXJ3; FOXO3; FOXP1; FOXP4 (directAnnotation).
COTL1	taipale_tf_pairs__E2F3_DRGX_SGCGCTAATTKN_CAP_repr	DRGX; E2F3 (directAnnotation).
COTL1	kznf__GTF3A_Schmitges2016_RCADE	GTF3A (directAnnotation).
COTL1	metacluster_22.15	BACH1 (directAnnotation).
COTL1	metacluster_22.14	BACH1 (inferredBy_Orthology).
COTL1	metacluster_145.4	ZNF716 (directAnnotation). FOXA2; FOXB2 (inferredBy_Orthology).
COTL1	transfac_pro__M06452	ZNF567 (directAnnotation).
COTL1	kznf__ZNF334_Imbeault2017_OM_MEME	ZNF334 (directAnnotation).

Page: 1 2 3 4 5

Top

Acts as a transcription factor

This table shows that this differential gene acts as a transcription factor.

Top

Acts as a drug target

This table shows that this differential gene acts as a drug target.

1	"Sun X, Zhang Y, Li H, Zhou Y, Shi S, Chen Z, He X, Zhang H, Li F, Yin J, Mou M, Wang Y, Qiu Y, Zhu F. DRESIS: the first comprehensive landscape of drug resistance information. Nucleic Acids Res. 2023 Jan 6;51(D1):D1263-D1275. doi: 10.1093/nar/gkac812. PMID: 36243960; PMCID: PMC9825618."
2	"Wishart DS, Feunang YD, Guo AC, Lo EJ, Marcu A, Grant JR, Sajed T, Johnson D, Li C, Sayeeda Z, Assempour N, Iynkkaran I, Liu Y, Maciejewski A, Gale N, Wilson A, Chin L, Cummings R, Le D, Pon A, Knox C, Wilson M. DrugBank 5.0: a major update to the DrugBank database for 2018. Nucleic Acids Res. 2018 Jan 4;46(D1):D1074-D1082. doi: 10.1093/nar/gkx1037. PMID: 29126136; PMCID: PMC5753335."